CD19 negative precursor B acute lymphoblastic leukemia (B‐ALL)—Immunophenotypic challenges in diagnosis and monitoring: A study of three cases

Abstract

Background CD19 is a B‐cell specific marker, expressed on all stages of B‐lymphocytes including plasma cells. It is widely used in the flow cytometric immunophenotyping (FCI) of B‐cell and plasma cell malignancies. The analysis approach of FCI for the diagnosis and monitoring of B‐cell acute lymphoblastic leukemia (B‐ALL) is totally based on the CD19‐based primary gating strategy and it would be challenging to study B‐ALL without CD19 expression. Since CD19 negative B‐ALL are extremely rare, we report three cases of B‐ALL with negative expression of CD19 and discussed its implication in the diagnosis, residual disease monitoring and future targeted therapy. Methods Peripheral blood (PB) and bone marrow (BM) samples from three cases suspicious of acute leukemia were studied for morphology, cytochemistry, immunophenotyping and cytogenetics. FCI was performed using a comprehensive six to eight‐color multiparametric assay. The cytogenetic studies for standard recurrent genetic translocations were performed by FISH & Karyotyping. Results The three cases studied were diagnosed as B‐ALL based on the expression of CD10, CD20, CD22, CD34, and CD79a by leukemic blasts. CD19 was studied using two different clones (i.e. J3‐119 & HIB‐19) and found to be severely down regulated in all three cases. There were no significant differentiating features in morphology. Cytogenetic studies were negative for recurrent translocations. Conclusion We report three cases of extremely rare CD19 negative B‐ALL. Lack of awareness of negative CD19 expression in B‐ALL can leads to incorrect immunophenotypic diagnosis and monitoring of B‐ALL, especially in laboratories using limited markers. © 2016 International Clinical Cytometry Society

CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy

“…CD19de novo B-ALL is very rare but reported. 32,33 A more common scenario is the loss of CD19 because of prior use of CD19-targeted immunotherapy. 11 We found that patients who were previously treated with blinatumomab had a significantly higher rate of failure to achieve MRDremission, and CD19 -MRD/relapse.…”

A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters

“…At the time that instructions for gating were initially distributed, we did not account for how to analyze dim CD191 cases even though antigen down-regulation has been documented (20)(21)(22). These presented a particular challenge, as this is the primary marker used to identify B-cell populations in the standard COG protocol.…”

CD72 is a pan‐tumor antigen associated to pediatric acute leukemia

“…In conclusion, we identified CD72 as a novel and robust pan‐acute leukemia TAA, strongly and specifically associated to pediatric BCP‐ALL as well as to half of the AML. Importantly, CD72 expression detected in blasts at diagnosis and at the time of molecular/overt relapse, including those characterized by CD19 loss [24, 25], strongly supports its use for advanced diagnostics. The potential of developing a novel immunotherapy approach with the unique potential of targeting both, acute lymphoid and myeloid leukemias, supports to advance CD72 pre‐clinical testing to provide a specific and selective cellular therapy.…”